Furiex Pharmaceuticals

Furiex Pharmaceuticals, Inc. is a drug development company primarily engaged in compound collaboration businesses in the United States. It partners with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its innovative drug development approaches. The company’s pipeline includes Eluxadoline1, a μ-opioid receptor agonist and δ-opioid receptor antagonist, currently in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D); and Avarofloxacin1, a fluoroquinolone antibiotic in Phase III development for the treatment of acute bacterial skin and skin structure infections.